Dr. Wetzler on Autologous Transplantation in Ph+ALL

Meir Wetzler, MD

Published Online: Tuesday, December 18, 2012

Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, explains the CALGB 10001 study analyzing autologous and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

The authors of the study hypothesized that an imatinib and sequential chemotherapy regimen would allow for the collection of a patient’s normal hematopoietic stem cells not contaminated by residual BCR/ABL+ lymphoblasts and reduce the likelihood of relapse after an autologous transplantation.

The study found that autologous transplantation is a safe and effective alternative to allogeneic transplantation for patients with Ph+ALL.

SEE ALL VIDEOS FROM: Meir Wetzler, MD

Related Articles

Primary Management of Advanced Hodgkin Lymphoma

The cure rate for patients who present with advanced Hodgkin lymphoma is significantly lower than those with early-stage disease. In this segment, the panel discusses variations that exist in the management of patients with advanced and early-stage Hodgkin lymphoma.

Resistance Poses Challenges in Chemotherapy Options

While chemotherapy might initially be effective in the treatment of patients with metastatic breast cancer, it is very common for patients to develop resistance to such agents.

Management of Hodgkin Lymphoma in Elderly Patients

Managing comorbid illnesses and poor tolerance to chemotherapy is a challenge facing the treatment of elderly patients with Hodgkin lymphoma. In this section, panelists discuss possible factors influencing worse outcomes in elderly patients.

Bringing the Oncology Community Together

Dr. Wetzler on Autologous Transplantation in Ph+ALL